Hologic, Inc. (HOLX) Stake Lessened by Achmea Investment Management B.V.

Achmea Investment Management B.V. cut its holdings in Hologic, Inc. (NASDAQ:HOLX) by 46.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,899 shares of the medical equipment provider’s stock after selling 10,217 shares during the period. Achmea Investment Management B.V.’s holdings in Hologic were worth $436,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in HOLX. Acadian Asset Management LLC bought a new position in Hologic during the second quarter valued at $1,648,000. Shell Asset Management Co. grew its holdings in Hologic by 0.8% during the second quarter. Shell Asset Management Co. now owns 24,847 shares of the medical equipment provider’s stock valued at $1,128,000 after purchasing an additional 200 shares during the period. Sumitomo Mitsui Asset Management Company LTD grew its holdings in Hologic by 2.5% during the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 21,870 shares of the medical equipment provider’s stock valued at $992,000 after purchasing an additional 525 shares during the period. Strs Ohio grew its holdings in Hologic by 49.0% during the second quarter. Strs Ohio now owns 42,706 shares of the medical equipment provider’s stock valued at $1,937,000 after purchasing an additional 14,049 shares during the period. Finally, Municipal Employees Retirement System of Michigan grew its holdings in Hologic by 27.5% during the second quarter. Municipal Employees Retirement System of Michigan now owns 24,810 shares of the medical equipment provider’s stock valued at $1,126,000 after purchasing an additional 5,350 shares during the period. 93.80% of the stock is owned by institutional investors and hedge funds.

Shares of Hologic, Inc. (HOLX) opened at $40.85 on Friday. The stock has a market capitalization of $11,030.00, a price-to-earnings ratio of 20.65, a price-to-earnings-growth ratio of 2.02 and a beta of 0.93. Hologic, Inc. has a 12-month low of $35.76 and a 12-month high of $46.80. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.01. The firm had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The business’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.52 earnings per share. sell-side analysts forecast that Hologic, Inc. will post 2.12 EPS for the current year.

In related news, Director Elaine Ullian sold 9,282 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Karleen Marie Oberton sold 1,023 shares of the stock in a transaction on Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 35,972 shares of company stock worth $1,385,977. Company insiders own 0.79% of the company’s stock.

Several brokerages have weighed in on HOLX. Barclays reissued an “equal weight” rating and set a $51.00 price objective (down from $53.00) on shares of Hologic in a report on Wednesday, August 9th. Piper Jaffray Companies reissued a “buy” rating and set a $48.00 price objective on shares of Hologic in a report on Thursday, November 9th. Royal Bank Of Canada reissued a “hold” rating and set a $42.00 price objective on shares of Hologic in a report on Friday, September 22nd. BidaskClub lowered Hologic from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. Finally, Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a report on Tuesday, October 31st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the company. Hologic has an average rating of “Buy” and a consensus target price of $47.54.

COPYRIGHT VIOLATION WARNING: “Hologic, Inc. (HOLX) Stake Lessened by Achmea Investment Management B.V.” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/12/02/hologic-inc-holx-stake-lessened-by-achmea-investment-management-b-v.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply